Coronavirus (Covid-19)Thailand

Patent application for antiviral drug Favipiravir rejected by Thai officials

Photo via Facebook/อนุทิน ชาญวีรกูล (Public Health Minister)

The patent application for the Japanese antiviral drug Favipiravir used to treat Covid-19 has been rejected in Thailand. With thousands of Covid-19 patients in hospitals and field hospitals, the Thai government made emergency orders for the drug, and sought permission for the right to produce the medicine locally.

An application had been filed under the compulsory license system where the government allows a company to produce a patented product in an emergency and for non-commercial use. The application was rejected by Thailand’s Intellectual Property Department and the department’s director general says it failed to meet the requirements for registration, according to a report by Thai PBS.

The director general says the drug can still be licensed for production for domestic use by the Ministry of Public Health. The applicant also has the right to appeal the ruling within the next 60 days.

Thailand has around 1.5 million Favipiravir pills and Thai healthcare workers have been using to treat patients with severe symptoms. The Thai government has ordered another 3 million tablets as the Covid-19 outbreak continues, with now around 30,000 active cases in Thailand with more than 1,000 patients in critical condition including hundreds on ventilators. The next shipment of Favipiravir tablets is expected to arrive in Thailand this month.


Join the conversation and have your say on Thailand news published on The Thaiger.

Thaiger Talk is our new Thaiger Community where you can join the discussion on everything happening in Thailand right now.

Please note that articles are not posted to the forum instantly and can take up to 20 min before being visible. Click for more information and the Thaiger Talk Guidelines.

Tanutam Thawan

Local Thai journalist speaking fluent Thai and English. Tanutam studied in Khon Kaen before attending Bangkok’s Chulalongkhorn University.

Leave a Reply